For Q1 FY2026 (ended March 31, 2026), Ceribell reported revenue of $26.5 million, up 29.3% year-over-year. Net loss was $19.7 million, a 54.5% increase from the prior year, with diluted EPS of -$0.52. Operating loss widened to $20.7 million. The company held $45.3 million in cash and $140.8 million in equity, with no long-term debt.
•Revenue grew 29.3% YoY to $26.5 million.
•Net loss increased 54.5% to $19.7 million; diluted EPS was -$0.52.
•Operating loss was $20.7 million, up 46.0% YoY.
•Cash balance of $45.3 million; no long-term debt.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
CeriBell is a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting
Disposable, flexible headbands, and headcaps. Its portfolio also includes a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals, and Clarity, an AI-powered seizure detection algorithm.
Additionally, it operates an EEG portal, which enables real-time remote access to a patient's EEG data. Incorporated in 2014 and headquartered in Sunnyvale, California, CeriBell was formerly known as Brain Stethoscope, Inc. before rebranding in August 2015.
CeriBell, Inc. is a medical technology company based in the United States that focuses on addressing unmet needs in acute care settings. The company developed the Ceribell System, a novel point-of-care EEG platform designed to rapidly assess brain activity in patients. Its portfolio includes disposable flexible headbands and headcaps, a pocket-sized rechargeable battery-operated recorder that captures and wirelessly transmits EEG signals, and Clarity, an AI-powered seizure detection algorithm. Additionally, CeriBell operates an EEG portal that enables real-time remote access to a patient's EEG data, facilitating timely clinical decisions. The company was formerly known as Brain Stethoscope, Inc. before rebranding in August 2015.
Where is CeriBell (CBLL) listed and what currency does it trade in?
CeriBell, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol CBLL. The company trades in United States Dollars (USD), which is the standard currency for stocks listed on U.S. exchanges. As a Nasdaq-listed company, CeriBell is subject to the exchange's listing requirements and regulatory oversight, providing investors with a transparent trading environment. The use of USD facilitates easy comparison with other U.S.-listed equities and simplifies transactions for domestic and international investors alike.
What sector and industry does CeriBell (CBLL) operate in?
CeriBell, Inc. operates in the Healthcare sector, specifically within the Medical Devices industry. As a medical technology company, it develops and commercializes innovative devices for neurological monitoring, particularly in acute care settings. The Medical Devices industry encompasses a wide range of products, from diagnostic equipment to therapeutic devices, and CeriBell's focus on EEG technology places it at the intersection of neurology and critical care. The company's products, such as the Ceribell System and Clarity AI algorithm, are designed to improve patient outcomes by enabling faster and more accurate detection of seizures and other brain abnormalities.
Where is CeriBell (CBLL) headquartered and what is its history?
CeriBell, Inc. is headquartered in Sunnyvale, California, United States. The company was incorporated in 2014 and was originally known as Brain Stethoscope, Inc. before rebranding to CeriBell in August 2015. Sunnyvale is located in the heart of Silicon Valley, a region known for its concentration of technology companies and innovation. Being based there allows CeriBell to tap into a rich ecosystem of talent, research institutions, and venture capital. The company's history reflects its evolution from a concept focused on a brain stethoscope to a full-fledged medical technology firm with a comprehensive EEG platform for acute care.
What are the key products and technologies of CeriBell (CBLL)?
CeriBell's key product is the Ceribell System, a point-of-care EEG platform designed for rapid brain monitoring in acute care settings. The system includes disposable flexible headbands and headcaps that are easy to apply, a pocket-sized rechargeable battery-operated recorder that captures and wirelessly transmits EEG signals, and Clarity, an AI-powered seizure detection algorithm that helps clinicians interpret data quickly. Additionally, the company offers an EEG portal that enables real-time remote access to a patient's EEG data, allowing specialists to review findings from anywhere. These technologies aim to streamline the diagnosis and management of seizures and other neurological conditions, reducing the time to treatment and improving patient outcomes.